Effects of schizonepetin on activity and mRNA expression of cytochrome P450 enzymes in rats

International Journal of Molecular Sciences

Volumn 13, Issue 12, 2012, Pages 17006-17018

  Bao, Beihua ^a   Geng, Ting ^b   Cao, Yudan ^a   Yao, Weifeng ^a   Zhang, Li ^a   Ding, Anwei ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b JIANGSU KANION PHARMACEUTICAL CO   (China)

Author keywords

Cytochrome P450; MRNA; Pharmacokinetic parameters; Real time RT PCR; Schizonepetin; Substrates drugs

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DAPSONE; MESSENGER RNA; METOPROLOL; OMEPRAZOLE; PHENACETIN; SCHIZONEPETIN; TERPENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; GENE EXPRESSION; HERB DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; LAMIACEAE; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LAMIACEAE; LIVER; MALE; MONOTERPENES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84871703510     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131217006     Document Type: Article

References (19)

1. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China; China Medical Science and Technology Press: Beijing, China, 2010; Volume 1, p. 216.
2. Ding, A.; Zhang, L.; Ding, J. Extraction and application of schizonepetin. Chinese Patent ZL01108186; 9 April 2001.
3. Zhang, L.; Zhang, M.; Sun, E.; Ding, A. Anti-inflammatory, and antipyretic effects of schizonepetolide polylactie-co-glycolic acid nanoparticles. J. China Pharm. Univ. 2008, 39, 433-436.
4. Zhu, H.; Zhang, L.; Yu, B.; Zhang, L.; Ding, A. Study on general Pharmacology of schizonepetin. Chin. J. Exp. Tradit. Med. Formulae 2011, 17, 237-240.
5. Liu, D.; Geng, T.; Zhang, L.; Yao, W.; Ding, A.; Shan, M. Acute and subacute toxicity and genotoxicity of schizonepetin, a naturally occurring monoterpene with antiviral activity. Food Chem. Toxicol. 2012, 50, 2256-2262.
6. Geng, T.; Sun, Y.; Yao, W.; Ding, A.; Zhang, L.; Guo, J.; Tang, Y. Pharmacokinetics and tissue distribution of schizonepetin in rats. Fitoterapia 2011, 82, 1110-1117.
7. Kim, E.; Lee, S.; Jung, H.; Jung, H.; Yeo, C.; Shon, J.; Shin, J. Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. Clin. Chim. Acta 2010, 411, 2043-2048.
8. Nebert, D.W.; Russell, D.W. Clinical importance of the cytochromes P450. Lancet 2002, 360, 1155-1162.
9. Hanapi, N.A.; Azizi, J., Ismail, S.; Mansor, S.M. Evaluation of selected Malaysian medicinal plants on phase I drug metabolizing enzymes, CYP2C9, CYP2D6 and CYP3A4 activities in vitro. Int. J. Pharmacol. 2010, 6, 494-499.
10. Rodriguez-Antona, C.; Ingelman-Sundberg, M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25, 1679-1691.
11. Nebert, D.W.; Dalton, T.P. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer 2006, 6, 947-960.
12. Bjornsson, T.D.; Callaghan, J.T.; Einolf, H.J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S.P.; Miwa, G.; Ni, L.; et al. The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31, 815-832.
13. Paolini, M.; Biagi, G.L.; Bauer, C.; Cantelliforti, G. Cocktail strategy: Complications and limitations. J. Clin. Pharmacol. 1993, 33, 1011-1012.
14. Zhou, H.H.; Tong, Z.; McLeod, J.F. "Cocktail" approaches and strategies in drug development: Valuable tool or flawed science? J. Clin. Pharmacol. 2004, 44, 120-134.
15. Hiratsuka, M. In vitro assessment of the allelic variants of cytochrome P450. Drug Metab. Pharmacokinet. 2012, 27, 68-84.
16. Kawase, A.; Fujii, A.; Negoro, M.; Akai, R.; Ishikubo, M.; Komura, H.; Iwaki, M. Differences in cytochrome P450 and nuclear receptor mRNA levels in liver and small intestines between SD and DA rats. Drug Metab. Pharmacokinet. 2008, 23, 196-206.
17. Lu, S.K.; Callahan, S.M.; Brunner, L.J. Suppression of hepatic CYP3A1/2 and CYP2C11 by cyclosporine is not mediated by altering growth hormone levels. J. Pharmacol. Exp. Ther. 2003, 305, 331-337.
18. Mustajoki, P.; Mustajoki, S.; Rautio, A.; Arvela, P.; Pelkonen, O. Effects of heme arginate on cytochrome P450-mediated metabolism of drugs in patients with variegate porphyria and in healthy men. Clin. Pharmacol. Ther. 1994, 56, 9-13.
19. Yao, X.; Wang, B.; Gu, Y.; Li, Y. Effects of bicyclol on the activity and expression of CYP450 enzymes of rats after partial hepatectomy. Acta Pharm. Sinica 2011, 46, 656-663.